<?xml version="1.0" encoding="UTF-8"?>
<p>On the other hand, observational cohort-controlled studies of patients with severe influenza due to the H3N2 subtype and H1N1 pandemic subtype treated in hospital with oseltamivir clearly demonstrate reduction in mortality, and this benefit was still observed if oseltamivir was started up to 4 to 5 days after the onset of symptoms (
 <xref rid="b7-idmm-26-e5" ref-type="bibr">7</xref>,
 <xref rid="b8-idmm-26-e5" ref-type="bibr">8</xref>). The majority of these patients usually had pre-existing risk factors for severe influenza, but approximately 30% were healthy younger persons with no discernable risk factors.
</p>
